Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Inhibikase Therapeutics Inc (IKT)

Inhibikase Therapeutics Inc (IKT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 125,542
  • Shares Outstanding, K 75,175
  • Annual Sales, $ 0 K
  • Annual Income, $ -27,520 K
  • EBIT $ -51 M
  • EBITDA $ -51 M
  • 60-Month Beta 0.84
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.69

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.13
  • Number of Estimates 2
  • High Estimate -0.12
  • Low Estimate -0.14
  • Prior Year N/A
  • Growth Rate Est. (year over year) -100.01%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.5500 +7.74%
on 12/17/25
2.1591 -22.65%
on 01/05/26
+0.0700 (+4.37%)
since 12/16/25
3-Month
1.3300 +25.56%
on 11/03/25
2.1591 -22.65%
on 01/05/26
+0.1600 (+10.60%)
since 10/16/25
52-Week
1.3300 +25.56%
on 11/03/25
3.3200 -49.70%
on 02/21/25
-1.0900 (-39.49%)
since 01/16/25

Most Recent Stories

More News
Inhibikase Therapeutics Announces Pricing of $100 Million Public Offering of Common Stock and Pre-Funded Warrants

WILMINGTON, Del., Nov. 20, 2025 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (NASDAQ: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing therapeutics to...

IKT : 1.6700 (+1.21%)
Inhibikase Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

BOSTON and ATLANTA, Nov. 20, 2025 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (NASDAQ: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing therapeutics...

IKT : 1.6700 (+1.21%)
Inhibikase Therapeutics Advancing IKT-001 to Global Phase 3 Study in Pulmonary Arterial Hypertension

Phase 3 Study initiating in First Quarter of 2026 Single Pivotal Study Accelerates Potential FDA Approval Timeline by Approximately 3 Years BOSTON and ATLANTA, Nov. 20, 2025 (GLOBE NEWSWIRE)...

IKT : 1.6700 (+1.21%)
Inhibikase Therapeutics Announces Third Quarter 2025 Financial Results and Highlights Recent Activity

BOSTON and ATLANTA, Nov. 14, 2025 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing therapeutics...

IKT : 1.6700 (+1.21%)
Inhibikase Therapeutics Strengthens Leadership Team with Appointment of Timothy Pigot as Chief Commercial and Strategy Officer

BOSTON and ATLANTA, Aug. 19, 2025 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing therapeutics...

IKT : 1.6700 (+1.21%)
Inhibikase Therapeutics Announces Second Quarter 2025 Financial Results and Highlights Recent Activity

BOSTON and ATLANTA, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing therapeutics...

IKT : 1.6700 (+1.21%)
Inhibikase Therapeutics Announces First Quarter 2025 Financial Results and Highlights Recent Activity

IKT : 1.6700 (+1.21%)
Inhibikase Therapeutics Announces Appointment of David McIntyre as Chief Financial Officer

IKT : 1.6700 (+1.21%)
Inhibikase Therapeutics Announces 2024 Financial Results and Highlights Recent Activity

IKT : 1.6700 (+1.21%)
Inhibikase Announces Expansion of Senior Leadership Team

IKT : 1.6700 (+1.21%)

Business Summary

Inhibikase Therapeutics Inc. is a clinical-stage pharmaceutical company. It engages in developing therapeutics for Parkinson's disease and related disorders. The company operates principally in Boston, Massachusetts. Inhibikase Therapeutics Inc. is headquartered in Atlanta, Georgia.

See More

Key Turning Points

3rd Resistance Point 1.8067
2nd Resistance Point 1.7633
1st Resistance Point 1.7167
Last Price 1.6700
1st Support Level 1.6267
2nd Support Level 1.5833
3rd Support Level 1.5367

See More

52-Week High 3.3200
Fibonacci 61.8% 2.5598
Fibonacci 50% 2.3250
Fibonacci 38.2% 2.0902
Last Price 1.6700
52-Week Low 1.3300

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar